Who invested in Ochre Bio

2 rounds we have observed, with the 4 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

BiotechHealthcarePharma

Y Combinator: W20

Funding summaryUpdated 26 Oct 2026

$30Mraised across 2 rounds since 2021, from 2 sources

Latest round: Series A, $30MOct 2022
Investors: 4

See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

2022

?Seed$30MSeries A

First round: Seed
Biggest round: $30M
Between rounds: 15 months

The rounds

Oct 2022
Series A$30M4 new
Source recorded
Jun 2021
SeedAmount undisclosed
No investor was named in the report.
Reported by Firms' own news pages

Founders and team

From Ochre Bio's own website: 1 founder, 17 on the team.

Quin WillsFounder & CEO

Jack CastleChief Business Officer
Sarah BateyChief Operating Officer
Fabio SannaHead of Discovery & Innovation
Ahmad Bashir BarekzaiClinical Research Scientist
Birbal PrasadSenior Scientist I
Cho-Chin ChengSenior Scientist I
Eduardo MartinsClinical Translation Board
Elaine SullivanBoard Member
Eliot ForsterBoard Chair
Giuseppe D'AgostinoPrincipal Scientist I
Jian-Hua WangResearch Associate II
Joanne SoongLab Manager
Johan LouwResearch Associate II
Jung-An LinResearch Associate I
Kayla LawrenceResearch Associate II
Ness BerminghamBoard Member
No LabExec and board

Who was in which round

The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.

Seed2021Series A2022

Everyone who backed them

Y CombinatorAccelerator1round

Khosla VenturesVC firm1round

ApolloPrivate equity1round

Backed VCVC firm1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

These 6 firms list Ochre Bio as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.